Enzymatica: First results from clinical study - Redeye

Redeye endorses the first results from Enzymatica’s ongoing independent clinical study at the University of Kent. The results show that ColdZyme significantly reduces viral load, and the participants experienced less severe sore throat symptoms. We argue the results will be positive from a marketing and future order perspective. However, we do not change our estimates upon today’s news and reiterate our base case of SEK6.5.

Länk till analysen i sin helhet: https://www.redeye.se/research/943806/enzymatica-first-results-from-clinical-study?utm_source=finwire&utm_medium=RSS